Therefore, whole-body evaluation using [89Zr]GPC1 mAb PET is an ideal method compared with biopsy from a single lesion or blood biomarker, because the former can assess only a portion of 1 lesion and the latter can provide averaged information irrespective of the overall tumor burden. This evidence concerns the gene GPC1 and neoplasm.